The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of neoadjuvant chemotherapy with a metronomic regimen of paclitaxel + cyclophosphamide + capecitabine followed by 5-fluorouracil + epirubicin + cyclophosphamide in operable triple-negative breast cancer (JBCRG-13 study).
Kenji Higaki
No relevant relationships to disclose
Norikazu Masuda
Honoraria - Chugai Pharma
Toshimi Takano
No relevant relationships to disclose
Nobuki Matsunami
No relevant relationships to disclose
Takashi Morimoto
No relevant relationships to disclose
Shoichiro Ohtani
No relevant relationships to disclose
Makiko Mizutani
No relevant relationships to disclose
Takeshi Miyamoto
No relevant relationships to disclose
Katsumasa Kuroi
No relevant relationships to disclose
Shinji Ohno
No relevant relationships to disclose
Satoshi Morita
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma
Masakazu Toi
Honoraria - Chugai Pharma
Research Funding - Bristol-Myers Squibb; Chugai Pharma